Organogenesis Holdings Inc.

NasdaqCM:ORGO Stock Report

Market Cap: US$422.9m

Organogenesis Holdings Management

Management criteria checks 2/4

Organogenesis Holdings' CEO is Gary Gillheeney, appointed in Jan 2014, has a tenure of 10.92 years. total yearly compensation is $6.24M, comprised of 14.6% salary and 85.4% bonuses, including company stock and options. directly owns 1.15% of the company’s shares, worth $4.88M. The average tenure of the management team and the board of directors is 7.3 years and 3.8 years respectively.

Key information

Gary Gillheeney

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage14.6%
CEO tenure10.9yrs
CEO ownership1.2%
Management average tenure7.3yrs
Board average tenure3.8yrs

Recent management updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Recent updates

Organogenesis: Lurking Disruption With Recovery To Follow

Oct 15

Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

Sep 09
Why Investors Shouldn't Be Surprised By Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Low P/S

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15
We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21
Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01
Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04
These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31
Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19
Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

CEO Compensation Analysis

How has Gary Gillheeney's remuneration changed compared to Organogenesis Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$7m

Jun 30 2024n/an/a

-US$17m

Mar 31 2024n/an/a

US$6m

Dec 31 2023US$6mUS$909k

US$5m

Sep 30 2023n/an/a

US$13m

Jun 30 2023n/an/a

US$10m

Mar 31 2023n/an/a

US$13m

Dec 31 2022US$6mUS$883k

US$16m

Sep 30 2022n/an/a

US$59m

Jun 30 2022n/an/a

US$71m

Mar 31 2022n/an/a

US$83m

Dec 31 2021US$4mUS$835k

US$94m

Sep 30 2021n/an/a

US$62m

Jun 30 2021n/an/a

US$69m

Mar 31 2021n/an/a

US$43m

Dec 31 2020US$3mUS$823k

US$17m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$37m

Mar 31 2020n/an/a

-US$42m

Dec 31 2019US$1mUS$819k

-US$39m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$48m

Mar 31 2019n/an/a

-US$58m

Dec 31 2018US$3mUS$798k

-US$65m

Sep 30 2018n/an/a

-US$60m

Jun 30 2018n/an/a

-US$52m

Mar 31 2018n/an/a

-US$32m

Dec 31 2017US$1mUS$780k

-US$9m

Compensation vs Market: Gary's total compensation ($USD6.24M) is above average for companies of similar size in the US market ($USD2.16M).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.

CEO

Gary Gillheeney (69 yo)

10.9yrs

Tenure

US$6,244,671

Compensation

Mr. Gary S. Gillheeney, Sr. has been the Chief Executive Officer and President of Organogenesis Holdings Inc. since 2014 and has been its Director since December 10, 2018 & serves as its Chair of the Board...

Leadership Team

NamePositionTenureCompensationOwnership
Gary Gillheeney
President10.9yrsUS$6.24m1.15%
$ 4.9m
David Francisco
Chief Financial Officer3.8yrsUS$1.63m0.048%
$ 203.7k
Patrick Bilbo
Chief Operating Officer7.3yrsUS$2.16m0.26%
$ 1.1m
Lori Freedman
Chief Administrative & Legal Officer7.9yrsUS$1.99m0.063%
$ 267.7k
Brian Grow
Chief Commercial Officer7.3yrsUS$1.92m0.078%
$ 331.2k
William Kolb
Secretaryno datano datano data
Robert Cavorsi
Vice President of Strategy3.9yrsno data0.11%
$ 445.8k

7.3yrs

Average Tenure

57.5yo

Average Age

Experienced Management: ORGO's management team is seasoned and experienced (7.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gary Gillheeney
President6yrsUS$6.24m1.15%
$ 4.9m
Glenn Nussdorf
Director21.9yrsno data8.99%
$ 38.0m
Alan Ades
Director21.9yrsno data8.44%
$ 35.7m
Arthur Leibowitz
Lead Independent Director6yrsUS$291.46k0.10%
$ 435.7k
Robert Ades
Director4.1yrsno datano data
Jon Giacomin
Independent Director3.6yrsUS$265.00k0.068%
$ 286.6k
Garrett Lustig
Directorless than a yearno data0.021%
$ 87.2k
Michele Korfin
Independent Director2.6yrsUS$226.98k0.068%
$ 286.0k
Prathyusha Duraibabu
Independent Director3.1yrsUS$240.00k0.071%
$ 299.3k
David Erani
Director4.1yrsno datano data
Michael Driscoll
Independent Director2.8yrsUS$230.52kno data
Gilberto Quintero
Independent Director2.6yrsUS$226.98k0.068%
$ 286.0k

3.8yrs

Average Tenure

59yo

Average Age

Experienced Board: ORGO's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 09:03
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Organogenesis Holdings Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Ross OsbornCantor Fitzgerald & Co.
Matthew MiksicCredit Suisse